Research programme: Nav1.7 voltage-gated sodium channel inhibitors - SiteOne Therapeutics

Drug Profile

Research programme: Nav1.7 voltage-gated sodium channel inhibitors - SiteOne Therapeutics

Alternative Names: GTX analogues - SiteOne Therapeutics; Guanidinium toxin analogues - SiteOne Therapeutics; NaV1.7 inhibitors - OneSite Therapeutics; Sodium ion channel 1.7 inhibitors - OneSite Therapeutics

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stanford University
  • Developer SiteOne Therapeutics
  • Class Imaging agents; Small molecules
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pain
  • Research Cancer; Muscle hypertonia; Pruritus

Most Recent Events

  • 26 Mar 2018 Preclinical trials in Pain in USA (PO) before March 2018
  • 06 Jan 2017 SiteOne Therapeutics and Amgen agree to develop NaV1.7 voltage-gated sodium channel inhibitors for Pain
  • 23 Sep 2014 Early research in Hypertonia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top